Moleculin Biotech, Inc. MBRX
Set alert
8.32 USD 0.00 0.00%
At close · Nov 2
8.26 -0.06 -0.70%
After hours · Nov 2, 4:00 PM ET
7.65 Day range 8.50
3.22 52-week range 253.00
- YTD
- +151.36%
- 1 year
- -28.46%
- Open
- 7.96
- Prev close
- 8.32
- Mkt cap
- 8.48M
- Vol
- 273
- Avg vol
- 51.75K
- EPS
- 179.60
- P/E
- 0.05
- Div yield
- 0.00%
More statistics
- Low
- 7.65
- High
- 8.50
- Forward P/E
- -0.29
- Beta
- 0.00
- Short ratio
- 0.36
- Inst. own
- 15.34%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 22, 2024
- 50-d avg
- 2.49
- 200-d avg
- 3.26
- 1y target
- 18.00
6M chart
Events in this range
- Oct 20, 2026Split: 1 for 20
Signals (23)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 13, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 30, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| RSI: Oversold | Jul 29, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 4 months ago |
| SMA: Bearish | Jul 6, 2026 | 4 months ago |
| MACD: Sell Signal | Jul 2, 2026 | 4 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 9, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
Newest 20 of 23.
Analyst view
Consensus: none
Price target (mean) 18.00 +116.3% upside
Now 8.32
- Target (low)
- 8.00
- Target (mean)
- 18.00
- Target (high)
- 28.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | -14.09 | -14.09 – -14.09 | -14.28 | +1.3% | 0 | 0.0% | 1 |
| Next year | -5.28 | -5.28 – -5.28 | -14.09 | +62.5% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | Maxim Group | Maintained | Buy | Buy |
| Apr 12, 2024 | Roth MKM | Maintained | Buy | Buy |
| Mar 26, 2024 | Maxim Group | Maintained | Buy | Buy |
| Dec 14, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Apr 18, 2023 | Roth MKM | Maintained | — | Buy |
| Mar 24, 2023 | Oppenheimer | Reiterated | — | Outperform |